Drugs / Nanoparticulate paclitaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00666991 | Jul 2008 → May 2013 | peritoneal neoplasm | CritiTech, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanoparticulate paclitaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00666991 ↗ |
| Known as | Nanotax | “Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity” NCT00666991 ↗ |
| Route | Other | “via intraperitoneal infusion” NCT00666991 ↗ |